Original Article
Solid Cancers after Bone Marrow Transplantation
N Engl J Med 1997; 336:897-904March 27, 1997
- Abstract
Background
The late effects of bone marrow transplantation, including cancer, need to be determined in a large population at risk.
Methods
We studied 19,229 patients who received allogeneic transplants (97.2 percent) or syngeneic transplants (2.8 percent) between 1964 and 1992 at 235 centers to evaluate the risk of the development of a new solid cancer. Risk factors relating to the patient, the transplant, and the course after transplantation were evaluated.
Results
The transplant recipients were at significantly higher risk of new solid cancers than the general population (observed cases, 80; ratio of observed to expected cases, 2.7; P<0.001). The risk was 8.3 times as high as expected among those who survived 10 or more years after transplantation. The cumulative incidence rate was 2.2 percent (95 percent confidence interval, 1.5 to 3.0 percent) at 10 years and 6.7 percent (95 percent confidence interval, 3.7 to 9.6 percent) at 15 years. The risk was significantly elevated (P<0.05) for malignant melanoma (ratio of observed to expected cases, 5.0) and cancers of the buccal cavity (11.1), liver (7.5), brain or other parts of the central nervous system (7.6), thyroid (6.6), bone (13.4), and connective tissue (8.0). The risk was higher for recipients who were younger at the time of transplantation than for those who were older (P for trend, <0.001). In multivariate analyses, higher doses of total-body irradiation were associated with a higher risk of solid cancers. Chronic graft-versus-host disease and male sex were strongly linked with an excess risk of squamous-cell cancers of the buccal cavity and skin.
Conclusions
Patients undergoing bone marrow transplantation have an increased risk of new solid cancers later in life. The trend toward an increased risk over time after transplantation and the greater risk among younger patients indicate the need for lifelong surveillance.
Media in This Article
Table 1
Characteristics of 19,229 Patients Undergoing Bone Marrow Transplantation.Table 2
Ratio of Observed to Expected Cases of New Invasive Solid Cancers According to the Time since Transplantation.Article Activity
- Article
Bone marrow transplantation is an increasingly effective treatment for leukemia and several other malignant and nonmalignant diseases. However, there is growing concern about possible late consequences of compromised immune function and of treatment, particularly new cancers resulting from the total-body irradiation and high-dose chemotherapy used as conditioning regimens for transplantation. Few studies have assessed the risk of cancer among long-term survivors of bone marrow transplantation.1-7 Some studies have shown a high risk of lymphoproliferative disorders after allogeneic bone marrow transplantation and statistically significant excesses of myelodysplastic syndromes and leukemia after autologous transplantation for lymphoma.2,7 Earlier studies of solid cancers that occurred after transplantation have been based on relatively small numbers of cases, and little information was available on individual cancers. Using a multi-institution data base that includes almost 20,000 recipients of allogeneic transplants, we conducted a study to determine the risk of new solid cancers after bone marrow transplantation.
Methods
Patients
A total of 19,229 patients who received allogeneic or syngeneic bone marrow transplants (97.2 percent and 2.8 percent, respectively) were identified from the International Bone Marrow Transplant Registry (IBMTR) and the Fred Hutchinson Cancer Research Center in Seattle. Data from the IBMTR, which covers 234 transplantation centers, included transplantations for the period from 1964 to 1990, with follow-up through 1991; the Seattle data were for the period from 1969 to 1992. The risk of new cancers in 1980 among the patients from Seattle2 and several centers covered by the IBMTR4,6,7 have been published previously. From the original cohort of 19,430, we excluded 201 patients with Fanconi's anemia and 376 with primary immunodeficiency diseases, because they have an inborn susceptibility to cancer.8,9
Most of the patients (75 percent) received transplants for leukemia, and most (79 percent) received bone marrow from an HLA-identical sibling. The median age at the time of transplantation was 25.5 years. Overall, 91 percent of the recipients were followed through the end date of the study. Among the 9501 patients who survived for at least 1 year after transplantation, the median duration of follow-up was 3.5 years (mean, 4.5; maximum, 25). Pathology reports and selected slides were reviewed centrally for 95 percent of the patients with new solid tumors.
Treatment and Risk Factors
The characteristics of the patients are shown in Table 1Table 1
Characteristics of 19,229 Patients Undergoing Bone Marrow Transplantation.. For patients with second cancers, information on prior therapy for the primary disease was abstracted from the transplantation center's records, but such data were generally unavailable for the other patients. Conditioning regimens for 14,000 patients (73 percent of the cohort) consisted of total-body irradiation combined with cyclophosphamide-based regimens (65 percent) or other drugs (8 percent). Another 656 patients (most of whom had aplastic anemia) received limited-field irradiation (total nodal, total lymphoid, or thoracoabdominal irradiation), without total-body irradiation. Patients who did not undergo irradiation typically received cyclophosphamide (22 percent), with or without other drugs.Prophylaxis against graft-versus-host disease included T-cell depletion of bone marrow; drug therapy with cyclosporine, methotrexate, corticosteroids, or other drugs; and combined therapies. Acute graft-versus-host disease was commonly treated with cyclosporine, antithymocyte or antilymphocyte globulin, corticosteroids, or a combination of these agents. Fewer than 550 patients were treated with methotrexate, azathioprine, or monoclonal antibodies for acute graft-versus-host disease. Information on drugs used to treat chronic graft-versus-host disease was incomplete and therefore not evaluated.
Statistical Analysis
For each transplant recipient, the number of person-years at risk was calculated from the date of transplantation until the date of last contact, death, diagnosis of a new cancer, or completion of the study, whichever occurred first. Age-, sex-, year-, and region-specific incidence rates for all solid cancers combined and for cancers at specific anatomical sites were applied to the appropriate person-years at risk to compute the expected numbers of cancers. Incidence rates for all invasive cancers (except nonmelanoma skin cancers) were obtained from selected registries in the United States, England and Wales, Europe, and Asia.10-12 Ratios of observed to expected cases and 95 percent confidence intervals were calculated on the assumption that the observed number of cancers followed a Poisson distribution.13 The absolute excess risk was calculated as the observed number of cancers minus the expected number of cancers per 10,000 transplant recipients per year. The cumulative probability of a new invasive solid cancer was estimated by the Kaplan–Meier method.14
Univariate and multivariate analyses were used to compare risks for various subgroups of transplant recipients who survived for at least one year after transplantation, with the use of Poisson regression methods for grouped survival data13,15 and Cox proportional-hazards regression techniques.16 These two approaches had nearly identical results, and only the results of the Poisson analyses are presented here. Since the risk of cancer may differ according to the disease for which the transplantation was performed, the data were stratified according to the primary disease in six categories: acute lymphoblastic leukemia, acute nonlymphocytic leukemia, chronic myelogenous leukemia, severe aplastic anemia, lymphoma, and other. The data were also stratified according to the interval since transplantation (with cutoff points at 2.5, 5, 7.5, 10, and 12.5 years). Analyses were further adjusted for the cohort (Seattle or IBMTR) and the age at the time of transplantation. Age was entered into the model with the use of three continuous variables: less than 10, 10 to 39, and 40 or more years. Occurrences of acute graft-versus-host disease (grades II to IV) and chronic graft-versus-host disease (moderate or severe disease in the IBMTR cohort and clinically extensive disease in the Seattle cohort) were entered as time-dependent covariates. Except where noted, Poisson regression analyses were performed for all invasive solid cancers except nonmelanoma skin cancer (71 cases among patients who survived for at least one year after transplantation); invasive squamous-cell skin cancers (8 cases) were considered separately.
Results
Among the 19,229 patients who underwent bone marrow transplantation, 80 new cases of invasive solid cancers were observed as compared with 29.8 expected cases in the general population (ratio of observed to expected cases, 2.7; P<0.001) (Table 2Table 2
Ratio of Observed to Expected Cases of New Invasive Solid Cancers According to the Time since Transplantation.). The risk of cancer was similar in the IBMTR cohort (observed cases, 49; ratio of observed to expected cases, 2.4) and the Seattle cohort (observed cases, 31; ratio of observed to expected cases, 3.2). The risks were significantly elevated for cancers of the buccal cavity (ratio of observed to expected cases, 11.1), liver (7.5), brain and other parts of the central nervous system (7.6), thyroid (6.6), bone (13.4), and connective tissue (8.0) and for melanoma (5.0). There was little increase in the risk of common adult cancers, such as breast cancer in women or digestive, respiratory, or genitourinary tract cancers in women or men. The overall risk rose steeply over time after transplantation, with a risk that was eight times as high as expected among patients who survived 10 or more years after transplantation (P for trend, <0.001). The cumulative incidence rate of new solid cancers 5, 10, and 15 years after transplantation was 0.7 percent (95 percent confidence interval, 0.4 to 0.9 percent), 2.2 percent (95 percent confidence interval, 1.5 to 3.0 percent), and 6.7 percent (95 percent confidence interval, 3.7 to 9.6 percent), respectively; the corresponding values for the general population were 0.3, 0.6, and 0.8 percent. Only 104 patients were followed for more than 15 years. The risks of cancers of the buccal cavity, brain, and thyroid tended to be highest five or more years after transplantation, whereas the risks of melanoma and cancers of bone and connective tissue were elevated throughout the follow-up period.Several unusual cancers were diagnosed. Two of the three liver cancers were malignant fibrous histiocytomas, which are extremely rare in the general population. One patient had Kaposi's sarcoma of the visceral organs (unrelated to the acquired immunodeficiency syndrome), and one patient had neuroblastoma of the nasal cavities. Bone and connective-tissue cancers included chondrosarcoma (three cases), osteosarcoma (one), rhabdomyosarcoma (two), fibrosarcoma (two), and unspecified bone sarcoma (one). Brain and spinal cord cancers included astrocytoma (four cases), glioblastoma (six), and primitive neuroectodermal cancer (one). Ten of the 11 brain cancers developed in patients with acute leukemia. Of the 11 invasive melanomas, 7 occurred in patients with acute nonlymphocytic leukemia; 5 were early-stage lesions (<0.6 mm in diameter, Clark level II), 5 were Clark level III or IV lesions (0.9 to 3.8 mm in diameter), and 1 was unclassified. All three salivary gland cancers were mucoepidermoid carcinomas.
Of the 80 patients with new cancers, 36 died. The new cancer was the primary cause of death in 26 (including 10 with brain tumors).
A strong relation was found between the patient's age at the time of transplantation and the risk of cancer. The risk for children who were under 10 years of age at the time of transplantation was 36.6 times as high as expected; the risk was 4.6 times as high as expected for those who were 10 to 29 years old at the time of transplantation and nearly normal for those who were 30 years or older (P for trend, <0.001) (Table 3Table 3
Ratio of Observed to Expected Cases and Absolute Excess Risk of New Invasive Solid Cancers According to Age at Transplantation.). The inverse association between risk and age persisted when the risk was evaluated with use of the absolute excess risk (P for trend, 0.002). Over half the excess solid tumors in the youngest age group were cancers of the brain (observed cases, 9; expected cases, 0.22) or thyroid (observed cases, 4; expected cases, 0.02), with 9 of these 13 tumors occurring in children who had undergone cranial irradiation before transplantation. When brain and thyroid cancers were excluded from the analysis, there was no difference in the absolute excess risk among the patients who were less than 10, 10 to 19, or 20 to 29 years old at the time of transplantation.The risk of solid cancer also varied according to the primary disease (Table 4Table 4
Ratio of Observed to Expected Cases and Absolute Excess Risk of New Invasive Solid Cancers According to Age at Transplantation and Primary Disease.) and tended to be highest for patients with acute leukemia. Significantly elevated risks were also found for patients with acute nonlymphocytic leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia who had undergone transplantation before the age of 30 years. Among the patients who were 30 years or older at the time of transplantation, only those with acute nonlymphocytic leukemia had a significantly increased risk of solid cancer (ratio of observed to expected cases, 2.3), and the excess risk of solid tumors for older patients was similar to that for the patients who underwent transplantation at a younger age (21.0 and 26.6, respectively).Table 5Table 5
Multivariate Analysis of Risk Factors for New Invasive Solid Cancers among Patients Who Survived for at Least One Year after Transplantation. shows the results of multivariate regression analyses for patients who survived for at least one year after transplantation. Ten potential risk factors were evaluated with adjustment for age, time since transplantation, and primary disease (model 1 in Table 5). Patients who underwent pretransplantation conditioning with radiation had an increased risk of cancer as compared with those who did not receive radiotherapy. The risk of cancer in transplant recipients who underwent limited-field irradiation was 18.4 times as high as the risk for those who did not undergo irradiation. The doubling of the risk among patients given total-body irradiation either as a single dose or in multiple fractions was not statistically significant. However, the risk increased significantly with increasing doses of radiation for both the patients who received a single dose and those who received multiple doses (model 2 in Table 5) (P for trend, 0.006 and 0.001, respectively). Among patients undergoing total-body irradiation with a single dose of 10 Gy or higher or fractionated doses totaling 13 Gy or higher, the risk was three to four times that among the patients who did not undergo irradiation. A similar dose–response pattern was found when we compared the risk with that in the general population: the ratio of observed to expected cases was 6.7 for patients receiving a single dose of 10 Gy or higher and 6.1 for those receiving fractionated doses totaling 13 Gy or higher. In these groups, the risk of a new cancer was highest among the patients who had survived for five or more years (9.3 and 14.4, respectively).Table 6Table 6
Risk Factors for New Invasive Solid Cancers among Patients Who Survived for at Least One Year after Transplantation, According to the Site of Cancer. shows the results of univariate and multivariate regression analyses for individual sites of invasive cancer among the patients surviving for at least one year after transplantation. Patients who received high doses of total-body irradiation had a significant increase in the risk of melanoma and an increased risk of cancer of the brain and thyroid. The risk of buccal cancer was particularly high after limited-field irradiation. Chronic graft-versus-host disease was associated with elevated risks of squamous-cell cancers of the buccal cavity and skin. Of the 16 cases in patients with chronic graft-versus-host disease, 11 occurred in those who had received immunosuppressive therapy for two or more years. Twenty-one of the 22 cases of squamous-cell buccal or skin cancer developed in male patients. Depletion of T cells in the donor marrow was associated with a relative risk of invasive melanoma of 4.5 (Table 6) and a relative risk of 5.9 when the two in situ cases and nine invasive cases were considered together (P = 0.02).The immunosuppressive drugs used to prevent or treat acute graft-versus-host disease had no apparent effect on the risk of a new solid cancer in univariate or multivariate analyses. The drugs used for pretransplantation conditioning, evaluated singly and in combination, were not significantly related to the risk of solid cancer.
Discussion
Our analysis of nearly 20,000 bone marrow recipients, including 3200 who survived for five or more years, revealed a high risk of specific solid cancers after transplantation. The risk increased sharply over time (to 6.7 percent at 15 years) and was highest among children who had undergone transplantation when they were less than 10 years old. Statistically significant increases in risk were confined to melanoma and cancers of the buccal cavity, brain, liver, thyroid, bone, and connective tissue. The increased risk of new solid cancers after bone marrow transplantation is likely to be related to pretransplantation conditioning with radiation, altered immune function, and prior treatment for the primary disease.
Previous studies have reported an increased incidence of new cancers after bone marrow transplantation, mainly lymphomas and hematopoietic disorders, which occurred early in the follow-up period.2,4-7,17-19 Lymphoproliferative disorders are the most common cancer in the first year after allogeneic bone marrow transplantation; most are related to compromised immune function and Epstein–Barr virus infection.2,7 The estimated 10-year cumulative incidence of lymphoma in our cohort is less than 1.5 percent, with no cases of lymphoma observed 10 or more years after transplantation.
Data on post-transplantation solid cancers are sparse. The two largest studies reported small numbers of cancers at individual anatomical sites and an overall risk that was two to three times as high as that in the general population.2,7 Studies in animals have also linked various solid tumors to bone marrow transplantation.18,20
Whole-body irradiation at the doses typically given to transplant recipients would be fatal without bone marrow transplantation. The transplantation experience is also unique because large doses of radiation are given to patients who will also have impaired immune function. In our study, the risk of a solid cancer among patients who survived for one or more years after transplantation rose with the dose of radiation, with three to four times the risk at the highest dose levels, as compared with those who did not receive radiation therapy. The elevated risks for several solid cancers are consistent with a radiogenic effect, especially for cancers of the thyroid, salivary gland, bone, connective tissue, and brain.21 The 18-fold risk of cancer in patients who received limited-field irradiation is almost entirely attributable to a higher-than-expected number of cancers after thoracoabdominal irradiation among patients with severe aplastic anemia who were treated at a single center, as reported previously.6,22
Radiogenic cancers generally have a long latent period, and the risk of such cancers is frequently high among patients undergoing irradiation at a young age.21,23 Transplant recipients routinely undergo thorough follow-up examinations, which may result in early detection of secondary cancers. We found that young children given radiotherapy as part of the conditioning regimen had a high risk of cancer of the brain or thyroid, and most of these patients had received cranial irradiation before transplantation. Radiogenic thyroid cancer has been reported in children exposed to high or low doses of radiation but not in adults.24,25 Higher than expected numbers of brain cancers have been reported among children treated with cranial irradiation at doses of 1 to 3 Gy for tinea capitis26 and 18 to 24 Gy for acute lymphoblastic leukemia.27
Studies of patients who were exposed to radiation have found increased risks of bone and connective-tissue cancers in these patients only when the radiation doses surpassed 10 Gy.28-30 We found an increased risk of salivary gland cancer after radiation therapy — three cases — which is consistent with the strong dose response of the mucoepidermoid carcinomas of the salivary gland reported among survivors of the atomic bomb.31
Patients with immunodeficiency diseases and those receiving immunosuppressive therapy for organ transplants are prone to the development of cancer at certain sites.32-34 We found no link between immune dysfunction (i.e., HLA-mismatched marrow transplants, T-cell depletion, or graft-versus-host disease) and an elevated risk of solid cancer (all types combined), nor could we confirm an excess risk associated with the administration of antithymocyte globulin for graft-versus-host disease.3 However, the large increase in the risk of melanoma in our study and the possible association of melanoma with T-cell depletion are consistent with the findings in immunosuppressed patients with renal allografts35 or malignant lymphoma.36,37 The mechanism of the association between melanoma and high doses of radiation is unclear, since melanoma has not previously been linked to ionizing radiation.21,23 Immunologic factors may also contribute to the increased risk of squamous-cell skin cancers after bone marrow or renal transplantation, especially in regions where one can be exposed to strong sunlight.33 Immunologic alterations may predispose patients to squamous-cell cancers of the buccal cavity, particularly in view of the association between oral mucositis and chronic graft-versus-host disease. A recent study of patients with aplastic anemia who underwent transplantation at the Fred Hutchinson Cancer Research Center in Seattle or Hôpital St. Louis in Paris showed that the incidence of solid tumors, predominantly tumors of the buccal cavity and skin, was significantly increased after the administration of azathioprine for chronic graft-versus-host disease.4 In immunosuppressed patients, oncogenic viruses such as human papillomaviruses may contribute to squamous-cell cancers of the skin and buccal mucosa after transplantation.32,38 The excess risk of squamous-cell cancers of the buccal cavity and skin among male patients is unexplained, but it may indicate an interaction between ionizing radiation, immunodeficiency, and other risk factors more prevalent among men than women.
In our study, only 690 transplant recipients were followed for 10 or more years, which limited our ability to estimate the risk of cancer among long-term survivors. Follow-up of recipients surviving 10 to 20 years after transplantation should clarify the risks of breast, lung, and other cancers that may arise only after a long latent period. The experience of patients with Hodgkin's disease and others who underwent irradiation at a young age21,23,39,40 indicates that the risk of cancer among patients who receive transplants at a young age and survive to adulthood may be even higher than that reported in our study.
Bone marrow transplantation prolongs survival or is curative in many patients with cancer or other life-threatening diseases. These benefits clearly outweigh the risks of late complications. However, our results should alert physicians that recipients of bone marrow transplants, particularly those receiving transplants at a young age, have an increased incidence of new solid cancers and that the excess risk of cancer rises sharply with time. Transplant recipients should be followed indefinitely to detect early cancer and precursor lesions (e.g., dysplastic nevi, actinic keratoses, and oral leukoplakia), and they should avoid carcinogenic exposures (e.g., exposure to tobacco), which may potentiate the risk of solid cancers.
Supported by contracts (CP-21161 and CP-21103) with and grants (P01-CA-18029, P01-CA-47748, P01-CA-18221, and P01-CA-15704) from the National Cancer Institute; a Public Health Service grant (P01-CA-40053) from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute; a grant (P01-HL-36444) from the National Heart, Lung, and Blood Institute; and by grants from the following: Alpha Therapeutic Corporation; Amgen, Inc.; Applied Immune Services; Amour Pharmaceutical Company; Astra Pharmaceutical; Baxter HealthCare Corporation; Bayer Corporation; Biogen; Blue Cross and Blue Shield Association; Lynde and Harry Bradley Foundation; Bristol-Myers Squibb Company; Frank G. Brotz Family Foundation; Center for Advanced Studies in Leukemia; Charles E. Culpeper Foundation; Eleanor Naylor Dana Charitable Trust; Eppley Foundation for Research; Genentech, Inc.; Glaxo Wellcome Company; Hoechst Marion Roussel, Inc.; Immunex Corporation; Kettering Family Foundation; Kirin Brewery Company; Robert J. Kleberg, Jr., and Helen C. Kleberg Foundation; Herbert H. Kohl Charities, Inc.; Eli Lilly Company Foundation; Nada and Herbert P. Mahler Charities; Milstein Family Foundation; Milwaukee Foundation/Elsa Schoeneich Research Fund; Samuel Roberts Noble Foundation; Ortho Biotech Corporation; John Oster Family Foundation; Elsa U. Pardee Foundation; Jane and Lloyd Pettit Foundation; Pfizer, Inc.; Pharmacia; RGK Foundation; Sandoz Pharmaceuticals; Schering–Plough International; Walter Schroeder Foundation; Stackner Family Foundation; Starr Foundation; Joan and Jack Stein Charities; and Wyeth–Ayerst Laboratories.
We are indebted to all the investigators and staff at the participating transplantation centers who contributed data to this study; to Keith Sullivan, Mary Flowers, Jean Sanders, and Ted Gooley at the Fred Hutchinson Cancer Research Center for their continuous support of the study; to Muriel Siadek, Kathy Erne, Janet Nims, Mariann Hansen, and Linda Glockling at the Fred Hutchinson Cancer Research Center and Sharon K. Nell and Diane Knutsen at the IBMTR for support in collecting data; to Kathy Chimes, Elena Adrianza, and Diane Fuchs from Westat Inc. for coordination of field studies; and to George Geise and Dennis Buckman from Information Management Services for computing support.
Source Information
From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (R.E.C., D.A.S., L.B.T., R.N.H., J.F.F., J.D.B.); the International Bone Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee (P.A.R., M.M.H., K.A.S.); the Fred Hutchinson Cancer Research Center, Seattle (H.J.D., R.P.W.); and Hôpital Saint Louis, Hématologie–Greffe de Moelle, Paris (G.S.).
Address reprint requests to Ms. Curtis at Executive Plaza North, Suite 408, National Cancer Institute, Bethesda, MD 20892.
Other authors were H. Gary Schoch, B.A., George E. Sale, M.D., and Rainer Storb, M.D. (Fred Hutchinson Cancer Research Center, Seattle); William D. Travis, M.D. (Armed Forces Institute of Pathology, Washington, D.C.); Hans-Jochem Kolb, M.D. (University of Munich, Munich, Germany); Robert Peter Gale, M.D., Ph.D. (Salick Health Care, Los Angeles); and Jakob R. Passweg, M.D. (International Bone Marrow Transplant Registry, Milwaukee).
- References
References
1
Kolb HJ ,Bender-Gotze C . Late complications after allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant 1990;6:61-72
Web of Science | Medline2
Witherspoon RP ,Fisher LD ,Schoch G , et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989;321:784-789
Full Text | Web of Science | Medline3
Witherspoon RP ,Deeg HJ ,Storb R . Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplant Sci 1994;4:33-41
Medline4
Deeg HJ ,Socie G ,Schoch G , et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996;87:386-392
Web of Science | Medline5
Lowsky R ,Lipton J ,Fyles G , et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994;12:2187-2192
Web of Science | Medline6
Socie G ,Henry-Amar M ,Bacigalupo A , et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993;329:1152-1157
Full Text | Web of Science | Medline7
Bhatia S ,Ramsay NKC ,Steinbuch M , et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-3639
Web of Science | Medline8
Lustig JP ,Lugassy G ,Neder A ,Sigler E . Head and neck carcinoma in Fanconi's anaemia -- report of a case and review of the literature. Eur J Cancer B Oral Oncol 1995;31:68-72
CrossRef9
Filipovich AH ,Mathur A ,Kamat D ,Shapiro RS . Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 1992;52:Suppl:5465s-5467s
Web of Science | Medline10
Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edward BK, eds. SEER cancer statistics review, 1973-1991: tables and graphs. Bethesda, Md.: National Cancer Institute, 1994. (NIH publication no. 94-2789.)
11
Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J, eds. Cancer incidence in five continents. Vol. 6. Lyon, France: International Agency for Research on Cancer, 1992. (IARC scientific publications no. 120.)
12
Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol. 5. Lyon, France: International Agency for Research on Cancer, 1987. (IARC scientific publications no. 88.)
13
Breslow NE, Day NE. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987. (IARC scientific publications no. 82.)
14
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science15
Preston DL, Lubin JH, Pierce DA. Epicure user's guide. Seattle: HiroSoft, 1993.
16
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22017
Vose JM ,Kennedy BC ,Bierman PJ ,Kessinger A ,Armitage JO . Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies. Cancer 1992;69:784-789
CrossRef | Web of Science | Medline18
Kolb HJ ,Guenther W ,Duell T , et al. Cancer after bone marrow transplantation. Bone Marrow Transplant 1992;10:Suppl 1:135-138
Web of Science | Medline19
Witherspoon RP ,Storb R ,Pepe M ,Longton G ,Sullivan KM . Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. Blood 1992;79:289-291
Web of Science | Medline20
Deeg HJ ,Witherspoon RP . Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am 1993;7:417-429
Web of Science | Medline21
United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and effects of ionizing radiation. New York: United Nations, 1994. (United Nations publication no. E.94.IX.11.)
22
Socie G ,Henry-Amar M ,Devergie A , et al. Poor clinical outcome of patients developing malignant solid tumors after bone marrow transplantation for severe aplastic anemia. Leuk Lymphoma 1992;7:419-423
CrossRef | Web of Science | Medline23
Thompson DE ,Mabuchi K ,Ron E , et al. Cancer incidence in atomic bomb survivors. II. Solid tumors, 1958-1987. Radiat Res 1994;137:Suppl:S17-S67[Erratum, Radiat Res 1994;139:129.]
CrossRef | Web of Science | Medline24
Ron E ,Lubin JH ,Shore RE , et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259-277
CrossRef | Web of Science | Medline25
Tucker MA ,Jones PH ,Boice JD Jr , et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. Cancer Res 1991;51:2885-2888
Web of Science | Medline26
Ron E ,Modan B ,Boice JD Jr , et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988;319:1033-1039
Full Text | Web of Science | Medline27
Neglia JP ,Meadows AT ,Robison LL , et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330-1336
Full Text | Web of Science | Medline28
Tucker MA ,D'Angio GJ ,Boice JD Jr , et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588-593
Full Text | Web of Science | Medline29
Eng C ,Li FP ,Abramson DH , et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85:1121-1128
CrossRef | Web of Science | Medline30
Hawkins MM ,Wilson LMK ,Burton HS , et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996;88:270-278
CrossRef | Web of Science | Medline31
Land CE ,Saku T ,Hayashi Y , et al. Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987: evaluation of radiation-related risk. Radiat Res 1996;146:28-36
CrossRef | Web of Science | Medline32
Kinlen LJ. Immunologic factors, including AIDS. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. 2nd ed. New York: Oxford University Press, 1996:532-45.
33
Sheil AG . Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc 1992;24:1275-1279
Web of Science | Medline34
Rabkin CS ,Yellin F . Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994;86:1711-1716
CrossRef | Web of Science | Medline35
Greene MH ,Young TI ,Clark WH Jr . Malignant melanoma in renal-transplant recipients. Lancet 1981;1:1196-1199
CrossRef | Web of Science | Medline36
Tucker MA ,Misfeldt D ,Coleman CN ,Clark WH Jr ,Rosenberg SA . Cutaneous malignant melanoma after Hodgkin's disease. Ann Intern Med 1985;102:37-41
Web of Science | Medline37
Travis LB ,Curtis RE ,Boice JD Jr ,Hankey BF ,Fraumeni JF Jr . Second cancers following non-Hodgkin's lymphoma. Cancer 1991;67:2002-2009
CrossRef | Web of Science | Medline38
Vittorio CC ,Schiffman MH ,Weinstock MA . Epidemiology of human papillomaviruses. Dermatol Clin 1995;13:561-574
Web of Science | Medline39
Hancock SL ,Tucker MA ,Hoppe RT . Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31
CrossRef | Web of Science | Medline40
Bhatia S ,Robison LL ,Oberlin O , et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-751
Full Text | Web of Science | Medline
- Citing Articles (235)
Citing Articles
1
Akihide Yoshimi, Go Yamamoto, Tadashi Goto, Kazuhiko Koike, Mineo Kurokawa. (2012) Hepatocellular carcinoma in cirrhotic liver with graft-versus-host disease. Annals of Hematology
CrossRef2
Aiko Kida, George B. McDonald. (2012) Gastrointestinal, Hepatobiliary, Pancreatic, and Iron-Related Diseases in Long-Term Survivors of Allogeneic Hematopoietic Cell Transplantation. Seminars in Hematology 49:1, 43-58
CrossRef3
Gerard Socié, J. Douglas Rizzo. (2012) Second Solid Tumors: Screening and Management Guidelines in Long-Term Survivors After Allogeneic Stem Cell Transplantation. Seminars in Hematology 49:1, 4-9
CrossRef4
Murat Surucu, Mete Yeginer, Gulbin O. Kavak, John Fan, James A. Radosevich, Bulent Aydogan. (2012) Verification of dose distribution for volumetric modulated arc therapy total marrow irradiation in a humanlike phantom. Medical Physics 39:1, 281
CrossRef5
Gerard Socié, K. Scott Baker, Smita Bhatia. (2012) Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 18:1, S139-S150
CrossRef6
Matthias Troeltzsch, Herbert Stimmer, Rupert Langer, Markus Troeltzsch, Timm Steiner, Klaus-Dietrich Wolff. (2012) High-Grade Supraclavicular Soft Tissue Sarcoma as Secondary Malignancy After Successful Treatment of Acute Myeloid Leukemia: Case Report and Literature Review. Journal of Oral and Maxillofacial Surgery
CrossRef7
Oana Paun, Hillard M. Lazarus. (2011) Novel Transplant Strategies in Adults with Acute Leukemia. Hematology/Oncology Clinics of North America 25:6, 1319-1339
CrossRef8
S. Rangwala, K.Y. Tsai. (2011) Roles of the immune system in skin cancer. British Journal of Dermatology 165:5, 953-965
CrossRef9
Ashwini Budrukkar, Sidramesh Muttagi, Tanveer Shahid, Pankaj Chatturvedi, Shripad Banavali, Sarbani Ghosh Laskar, Vedang Murthy, Anil D’Cruz, Jai Prakash Agarwal. (2011) Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia. British Journal of Oral and Maxillofacial Surgery
CrossRef10
Bulent Aydogan, Mete Yeginer, Gulbin O. Kavak, John Fan, James A. Radosevich, Kim Gwe-Ya. (2011) Total Marrow Irradiation With RapidArc Volumetric Arc Therapy. International Journal of Radiation Oncology*Biology*Physics 81:2, 592-599
CrossRef11
Jonathan V. Feldstein, Javier Bolaños-Meade, Viki L. Anders, Rachel Abuav. (2011) Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. Journal of the American Academy of Dermatology 65:4, 733-738
CrossRef12
Navneet S. Majhail. (2011) Secondary cancers following allogeneic haematopoietic cell transplantation in adults. British Journal of Haematology 154:3, 301-310
CrossRef13
Smita Bhatia. (2011) Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Review of Hematology 4:4, 437-454
CrossRef14
Sabine Bieri, Eddy Roosnek, Hulya Ozsahin, Saadia Huguet, Marc Ansari, Andrea Trombetti, Claudine Helg, Bernard Chapuis, Raymond Miralbell, Jakob Passweg, Yves Chalandon. (2011) Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation. European Journal of Haematology 87:2, 138-147
CrossRef15
A M J Braamse, M M J G Gerrits, B van Meijel, O Visser, P van Oppen, A D Boenink, P Cuijpers, P C Huijgens, A T F Beekman, J Dekker. (2011) Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies. Bone Marrow Transplantation
CrossRef16
C. Marks, M. Stadler, P. Häusermann, D. Wolff, S. Buchholz, G. Stary, S. Lee, A. Lawitschka, H. Bertz. (2011) German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. British Journal of Dermatology 165:1, 18-29
CrossRef17
STEPHANIE W. HU, JONATHAN COTLIAR. (2011) Acute graft-versus-host disease following hematopoietic stem-cell transplantation. Dermatologic Therapy 24:4, 411-423
CrossRef18
H Mawardi, S Elad, M E Correa, K Stevenson, S-B Woo, S Almazrooa, R Haddad, J H Antin, R Soiffer, N Treister. (2011) Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplantation 46:6, 884-891
CrossRef19
Su-Peng Yeh, Wen-Jyi Lo, Chiao-Lin Lin, Yu-Min Liao, Chen-Yuan Lin, Li-Yuan Bai, Ji-An Liang, Chang-Fang Chiu. (2011) Anti-leukemic therapies induce cytogenetic changes of human bone marrow-derived mesenchymal stem cells. Annals of Hematology
CrossRef20
L. Montebugnoli, D.B. Gissi, C. Marchetti, M.P. Foschini. (2011) Multiple squamous cell carcinomas of the oral cavity in a young patient with graft-versus-host disease following allogenic bone marrow transplantation. International Journal of Oral and Maxillofacial Surgery 40:5, 556-558
CrossRef21
Stephanie M. Coomes, Leah L. N. Hubbard, Bethany B. Moore. (2011) Impaired pulmonary immunity post-bone marrow transplant. Immunologic Research 50:1, 78-86
CrossRef22
Naynesh R. Kamani, Shimareet Kumar, Anna Hassebroek, Mary Eapen, Jennifer LeRademacher, James Casper, Morton Cowan, José Sánchez de Toledo, Alina Ferster, Paul Szabolcs, John R. Wingard, Edwin Horwitz, Alexandra H. Filipovich. (2011) Malignancies after Hematopoietic Cell Transplantation for Primary Immune Deficiencies: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation
CrossRef23
C E Hill-Kayser, J P Plastaras, Z Tochner, E Glatstein. (2011) TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplantation 46:4, 475-484
CrossRef24
Johannes K.-H. Meier, Daniel Wolff, Steve Pavletic, Hildegard Greinix, Martin Gosau, Hartmut Bertz, Stefanie J. Lee, Ánita Lawitschka, Sharon Elad. (2011) Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clinical Oral Investigations 15:2, 127-139
CrossRef25
Emma J. Davies, Victoria Marsh, Alan R. Clarke. (2011) Origin and maintenance of the intestinal cancer stem cell. Molecular Carcinogenesis 50:4, 254-263
CrossRef26
M H Chen, P M Chang, W Y Li, L T Hsiao, Y C Hong, C Y Liu, J P Gau, J H Liu, P M Chen, T J Chiou, C H Tzeng. (2011) High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan. Bone Marrow Transplantation 46:4, 567-572
CrossRef27
K M Hull, I Kerridge, M Schifter. (2011) Long-term oral complications of allogeneic haematopoietic SCT. Bone Marrow Transplantation
CrossRef28
A Yokota, S Ozawa, T Masanori, H Akiyama, K Ohshima, Y Kanda, S Takahashi, T Mori, C Nakaseko, M Onoda, K Kishi, N Doki, N Aotsuka, H Kanamori, A Maruta, H Sakamaki, S Okamoto. (2011) Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplantation
CrossRef29
N. S. Majhail, R. Brazauskas, J. D. Rizzo, R. M. Sobecks, Z. Wang, M. M. Horowitz, B. Bolwell, J. R. Wingard, G. Socie. (2011) Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 117:1, 316-322
CrossRef30
J. Rosenthal, J. Wong, A. Stein, D. Qian, D. Hitt, H. Naeem, A. Dagis, S. H. Thomas, S. Forman. (2011) Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. Blood 117:1, 309-315
CrossRef31
Ka Hee Yi, Young Joo Park, Sung-Soo Koong, Jung-Han Kim, Dong Gyu Na, Jin-Sook Ryu, So Yeon Park, In Ae Park, Chung-Hwan Baek, Young Kee Shong, Young Don Lee, Jaetae Lee, Jeong Hyun Lee, Jae Hoon Chung, Chan Kwon Jung, Seung-Ho Choi, Bo Youn Cho. (2011) Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery 54:1, 8
CrossRef32
Eun-Oh Kim, Hee-Je Kim, Ki-Seong Eom, Byung-Sik Cho, Sung-Eun Lee, Seung-Ah Yahng, Jong-Wook Lee, Woo-Sung Min. (2011) Second Primary Glioblastoma Multiforme Following Autologous Hematopoietic Stem Cell Transplantation in a Patient with Acute Myelogenous Leukemia. Cancer Research and Treatment 43:3, 195
CrossRef33
Bryan Corrin, Andrew G. Nicholson. 2011. Tumours. , 531-705.
CrossRef34
B. N. Savani, M. L. Griffith, S. Jagasia, S. J. Lee. (2010) How I treat late effects in adults after allogeneic stem cell transplantation. Blood
CrossRef35
M Schlaak, S Schwind, T Wetzig, J Maschke, R Treudler, N Basara, T Lange, J C Simon, D Niederwieser, H K Al-Ali. (2010) UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplantation 45:12, 1741-1748
CrossRef36
K S Baker, K K Ness, D Weisdorf, L Francisco, C-L Sun, S Forman, S Bhatia. (2010) Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia 24:12, 2039-2047
CrossRef37
P. Dillon, N. Thomas, N. Sharpless, F. Collichio. (2010) Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Medical Oncology 27:4, 1127-1132
CrossRef38
Sharon Elad, Yehuda Zadik, Itai Zeevi, Akihiro Miyazaki, Maria A. Z. de Figueiredo, Reuven Or. (2010) Oral Cancer in Patients After Hematopoietic Stem-Cell Transplantation: Long-Term Follow-Up Suggests an Increased Risk for Recurrence. Transplantation 90:11, 1243-1244
CrossRef39
K. A. Lebedev. (2010) Homeostasis of adult human stem cells and carcinogenesis. Human Physiology 36:6, 621-628
CrossRef40
Yoko Ogawa, Shigeto Shimmura, Murat Dogru, Kazuo Tsubota. (2010) Immune Processes and Pathogenic Fibrosis in Ocular Chronic Graft-Versus-Host Disease and Clinical Manifestations after Allogeneic Hematopoietic Stem Cell Transplantation. Cornea 29, S68-S77
CrossRef41
F. M. Khan, S. Sy, P. Louie, A. Ugarte-Torres, N. Berka, G. D. Sinclair, D. A. Stewart, J. A. Russell, J. Storek. (2010) Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa. Blood 116:10, 1803-1806
CrossRef42
Y. Hosoya, A. Lefor, Y. Hirashima, M. Nokubi, T. Yamaguti, Y. Jinbu, K. Muroi, M. Nakazawa, Y. Yasuda. (2010) Successful Treatment of Esophageal Squamous Cell Carcinoma in a Patient with Fanconi Anemia. Japanese Journal of Clinical Oncology 40:8, 805-810
CrossRef43
Yoichiro Kusunoki, Kanya Hamasaki, Kazuaki Koyama, Kazue Imai, Tomonori Hayashi, Paul J. Martin, Kei Nakachi. (2010) Increased DNA damage in hematopoietic cells of mice with graft-versus-host disease. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 689:1-2, 59-64
CrossRef44
Karen K. Ballen, Corey Cutler, Beow Y. Yeap, Steven L. McAfee, Bimalangshu R. Dey, Eyal C. Attar, Yi-Bin Chen, Richard L. Haspel, Deborah Liney, John Koreth, Vincent Ho, Edwin P. Alyea, Robert J. Soiffer, Thomas R. Spitzer, Joseph H. Antin. (2010) Donor-Derived Second Hematologic Malignancies after Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 16:7, 1025-1031
CrossRef45
Miranda Paraskeva, Catriona McLean, Greg I. Snell, Glen P. Westall. (2010) Lung transplant survival despite unexpected pulmonary metastatic thyroid cancer in the explant. Transplant Internationalno-no
CrossRef46
Noelle V. Frey, David L. Porter. (2010) Hematopoietic stem cell transplantation: ASBMT/CIBMTR 2010 tandem meeting highlights and discussion. American Journal of Hematology 85:7, 519-523
CrossRef47
K Noguchi, M Nakase, M Inui, S Nakamura, K Okumura, T Tagawa. (2010) A case of tongue carcinoma associated with chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Australian Dental Journal 55:2, 200-202
CrossRef48
Ic S. Choi, Hoon Kook, Dong Y. Kim, Dong K. Han, Hee J. Baek, Kyung W. Suh, Young J. Kim, Jae H. Lee, Tai J. Hwang. (2010) Disseminated colon cancer in a 15-year-old boy after immunosuppression for aplastic anemia. Pediatrics International 52:2, 307-309
CrossRef49
Pablo F Peñas, Sarah Zaman. (2010) Many faces of graft- versus -host disease. Australasian Journal of Dermatology 51:1, 1-10
CrossRef50
Joseph Pidala, Claudio Anasetti, Heather Jim. (2010) Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. British Journal of Haematology 148:3, 373-385
CrossRef51
Ian Guest, Zoran Ilic, Jun Ma, Denise Grant, Gennadi Glinsky, Stewart Sell. (2010) Direct and indirect contribution of bone marrow-derived cells to cancer. International Journal of CancerNA-NA
CrossRef52
D Bresters, I C M van Gils, W J W Kollen, L M Ball, W Oostdijk, J G van der Bom, R M Egeler. (2010) High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplantation 45:1, 79-85
CrossRef53
Ka Hee Yi, Young Joo Park, Sung-Soo Koong, Jung-Han Kim, Dong Gyu Na, Jin-Sook Ryu, So Yeon Park, In Ae Park, Chung-Hwan Baek, Young Kee Shong, Young Don Lee, Jaetae Lee, Jeong Hyun Lee, Jae Hoon Chung, Chan Kwon Jung, Seung-Ho Choi, Bo Youn Cho. (2010) Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. Endocrinology and Metabolism 25:4, 270
CrossRef54
T Cluzeau, A Sirvent, S Lassalle, J Mouroux, N Mounier. (2010) Pneumoblastoma: a rare lung tumour occurring as a long-term complication after allogeneic haematopoietic cell transplantation. Bone Marrow Transplantation 45:1, 197-198
CrossRef55
Yifu Zhou, Suna Wang, Zuxi Yu, Robert F. Hoyt, Vandana Sachdev, Pamela Vincent, Andrew E. Arai, Minjung Kwak, Sandra Sczerba Burkett, Keith A. Horvath. (2009) Direct injection of autologous mesenchymal stromal cells improves myocardial function. Biochemical and Biophysical Research Communications 390:3, 902-907
CrossRef56
David S. Cooper, Gerard M. Doherty, Bryan R. Haugen, Richard T. Kloos, Stephanie L. Lee, Susan J. Mandel, Ernest L. Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger, Steven I. Sherman, David L. Steward, R. Michael Tuttle. (2009) Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19:11, 1167-1214
CrossRef57
André Tichelli, Alicia Rovó, Jakob Passweg, Carl Philipp Schwarze, Maria Teresa Van Lint, Mutlu Arat, Gérard Socié. (2009) Late complications after hematopoietic stem cell transplantation. Expert Review of Hematology 2:5, 583-601
CrossRef58
Ian Nivison-Smith, Judy M. Simpson, Anthony J. Dodds, David D.F. Ma, Jeff Szer, Kenneth F. Bradstock. (2009) Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates. Biology of Blood and Marrow Transplantation 15:10, 1323-1330
CrossRef59
I. G. M. Pas-van Voskuilen, J. S. J. Veerkamp, J. E. Raber-Durlacher, D. Bresters, A. J. Wijk, A. Barasch, S. McNeal, R. A. Th. Gortzak. (2009) Long-term adverse effects of hematopoietic stem cell transplantation on dental development in children. Supportive Care in Cancer 17:9, 1169-1175
CrossRef60
T H Schreiber, E R Podack. (2009) A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas. British Journal of Cancer 101:3, 381-386
CrossRef61
Pascal Pommier, Marie Pierre Sunyach, Caroline Pasteuris, Didier Frappaz, Christian Carrie. (2009) Second Cancer After Total-body Irradiation (TBI) in Childhood. Strahlentherapie und Onkologie 185:S2, 13-16
CrossRef62
M. M. Hsieh, C. D. Fitzhugh, J. F. Tisdale. (2009) Incidence of second cancers after allogeneic hematopoietic stem cell transplantation using reduced-dose radiation. Blood 114:1, 225-225
CrossRef63
J. Pidala, C. Anasetti, H. Jim. (2009) Quality of life after allogeneic hematopoietic cell transplantation. Blood 114:1, 7-19
CrossRef64
H.G. Sayer, D.W. Beelen. (2009) Hämatopoetische Stammzelltransplantation. Der Onkologe 15:6, 564-574
CrossRef65
Borje S Andersson, Marcos de Lima, Peter F Thall, Timothy Madden, James A Russell, Richard E Champlin. (2009) Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Current Opinion in Oncology 21:Suppl 1, S11-S15
CrossRef66
Y.-J. Kim, Y.-S. Kim, A. Larochelle, G. Renaud, T. G. Wolfsberg, R. Adler, R. E. Donahue, P. Hematti, B.-K. Hong, J. Roayaei, K. Akagi, J. M. Riberdy, A. W. Nienhuis, C. E. Dunbar, D. A. Persons. (2009) Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells. Blood 113:22, 5434-5443
CrossRef67
Stefan O. Ciurea, Borje S. Andersson. (2009) Busulfan in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 15:5, 523-536
CrossRef68
Kei Tomihara, Hironari Dehari, Akira Yamaguchi, Masato Abe, Akihiro Miyazaki, Kenji Nakamori, Masato Hareyama, Hiroyoshi Hiratsuka, Eben L. Rosenthal. (2009) Squamous cell carcinoma of the buccal mucosa in a young adult with history of allogeneic bone marrow transplantation for childhood acute leukemia. Head & Neck 31:4, 565-568
CrossRef69
Joel B. Epstein, Judith E. Raber-Drulacher, Affi Wilkins, Maria-Gabriella Chavarria, Han Myint. (2009) Advances in hematologic stem cell transplant: An update for oral health care providers. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 107:3, 301-312
CrossRef70
Jeffrey L. Schwartz, Kenneth J. Kopecky, Robert W. Mathes, Wendy M. Leisenring, Debra L. Friedman, H. Joachim Deeg. (2009) Basal Cell Skin Cancer after Total-Body Irradiation and Hematopoietic Cell Transplantation. Radiation Research 171:2, 155-163
CrossRef71
Mehmet Ertem, Talia Ileri, Fatih Azik, Zumrut Uysal, Sevgi Gozdasoglu. (2009) Related donor hematopoietic stem cell transplantation for Fanconi anemia without radiation: A single center experience in Turkey. Pediatric Transplantation 13:1, 88-95
CrossRef72
Tara Seshadri, Melania Pintilie, John Kuruvilla, Armand Keating, Richard Tsang, Sahar Zadeh, Michael Crump. (2009) Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 50:3, 380-386
CrossRef73
Houda Boukheris, Elaine Ron, Graça M. Dores, Marilyn Stovall, Susan A. Smith, Rochelle E. Curtis. (2008) Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma. Cancer 113:11, 3153-3159
CrossRef74
Mary Eapen, Vanderson Rocha. (2008) Principles and analysis of hematopoietic stem cell transplantation outcomes: the physician’s perspective. Lifetime Data Analysis 14:4, 379-388
CrossRef75
Hillard M. Lazarus, Jeanette Carreras, Christian Boudreau, Fausto R. Loberiza, James O. Armitage, Brian J. Bolwell, César O. Freytes, Robert Peter Gale, John Gibson, Gregory A. Hale, David J. Inwards, Charles F. LeMaistre, Dipnarine Maharaj, David I. Marks, Alan M. Miller, Santiago Pavlovsky, Harry C. Schouten, Koen van Besien, Julie M. Vose, Jacob D. Bitran, Issa F. Khouri, Philip L. McCarthy, Hongmei Yu, Philip Rowlings, Derek S. Serna, Mary M. Horowitz, J. Douglas Rizzo. (2008) Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR). Biology of Blood and Marrow Transplantation 14:12, 1323-1333
CrossRef76
J. E. Sanders, P. A. Hoffmeister, A. E. Woolfrey, P. A. Carpenter, B. E. Storer, R. F. Storb, F. R. Appelbaum. (2008) Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood 113:2, 306-308
CrossRef77
J. D. Rizzo, R. E. Curtis, G. Socie, K. A. Sobocinski, E. Gilbert, O. Landgren, L. B. Travis, W. D. Travis, M. E. D. Flowers, D. L. Friedman, M. M. Horowitz, J. R. Wingard, H. J. Deeg. (2008) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:5, 1175-1183
CrossRef78
X George Xu, Bryan Bednarz, Harald Paganetti. (2008) A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Physics in Medicine and Biology 53:13, R193-R241
CrossRef79
G C Prendergast. (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27:28, 3889-3900
CrossRef80
A Cohen, A N Békássy, A Gaiero, M Faraci, S Zecca, A Tichelli, G Dini. (2008) Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplantation 41, S43-S48
CrossRef81
M Faraci, A N Békássy, V De Fazio, A Tichelli, G Dini. (2008) Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplantation 41, S49-S57
CrossRef82
Miguel R. Campanero. (2008) Mechanisms involved in Burkitt’s lymphoma tumor formation. Clinical and Translational Oncology 10:5, 250-255
CrossRef83
MA Gonzalez-Moles, C Scully, JA Gil-Montoya. (2008) Oral lichen planus: controversies surrounding malignant transformation. Oral Diseases 14:3, 229-243
CrossRef84
Luca Laurenti, Michela Tarnani, Patrizia Chiusolo, Giuseppe La Torre, Mariagrazia Garzia, Marcella Zollino, Gina Zini, Mario Balducci, Giuseppe Leone, Simona Sica. (2008) Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy. Clinical Transplantation 22:2, 191-199
CrossRef85
Jyothi P. Jagannathan, Nikhil Ramaiya, Ritu R. Gill, Edwin Pascal Alyea, Pablo Ros. (2008) Imaging of Complications of Hematopoietic Stem Cell Transplantation. Radiologic Clinics of North America 46:2, 397-417
CrossRef86
Vincenzo Silani, Lidia Cova. (2008) Stem cell transplantation in Multiple Sclerosis: Safety and Ethics. Journal of the Neurological Sciences 265:1-2, 116-121
CrossRef87
D. L. Friedman, A. Rovo, W. Leisenring, A. Locasciulli, M. E. D. Flowers, A. Tichelli, J. E. Sanders, H. J. Deeg, G. Socie. (2008) Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 111:2, 939-944
CrossRef88
Thomas Lowe, Thehang Luu, Jeannie Shen, George Somlo. (2008) Male Breast Cancer 15 Years after Allogeneic Hematopoietic Cell Transplantation Including Total Body Irradiation for Recurrent Acute Lymphoblastic Leukemia. Onkologie 31:5, 266-269
CrossRef89
June-Ho Byun, Bong-Wook Park, Jong-Ryoul Kim, Gyeong-Won Lee, Jeong-Hee Lee. (2008) Squamous Cell Carcinoma of the Tongue After Bone Marrow Transplant and Graft-Versus-Host Disease: A Case Report and Review of the Literature. Journal of Oral and Maxillofacial Surgery 66:1, 144-147
CrossRef90
Ralf A. Schneider, Juergen Schultze, J. Martin Jensen, Dieter Hebbinghaus, Razvan M. Galalae. (2008) Long-Term Outcome After Static Intensity-Modulated Total Body Radiotherapy Using Compensators Stratified by Pediatric and Adult Cohorts. International Journal of Radiation Oncology*Biology*Physics 70:1, 194-202
CrossRef91
Johannes L. Zakrzewski, Gabrielle L. Goldberg, Odette M. Smith, Marcel R.M. van den Brink. (2008) Enhancing T cell reconstitution after hematopoietic stem cell transplantation: A brief update of the latest trends. Blood Cells, Molecules, and Diseases 40:1, 44-47
CrossRef92
N. S. Majhail. (2008) Old and New Cancers after Hematopoietic-Cell Transplantation. Hematology 2008:1, 142-149
CrossRef93
Emmanuelle Tavernier, Quoc-Hung Le, Stéphane de Botton, Nathalie Dhédin, Claude-Eric Bulabois, Oumedaly Reman, Norbert Vey, Véronique Lhéritier, Hervé Dombret, Xavier Thomas. (2007) Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. Cancer 110:12, 2747-2755
CrossRef94
Masataka Ishimura, Shouichi Ohga, Yoshihisa Nagatoshi, Jun Okamura, Tatsuro Tajiri, Kenichi Kohashi, Yoshinao Oda, Hidetoshi Takada, Toshiro Hara. (2007) Malignant hepatic tumor occurring 10 yrs after a histocompatible sibling donor bone marrow transplantation for severe aplastic anemia. Pediatric Transplantation 11:8, 945-949
CrossRef95
G Michel, P Bordigoni, M-C Simeoni, C Curtillet, S Hoxha, S Robitail, I Thuret, S Pall-Kondolff, H Chambost, D Orbicini, P Auquier. (2007) Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation. Bone Marrow Transplantation 40:9, 897-904
CrossRef96
Osman Köse, Ahmet Emin Kürekçi, Mükerrem Safali, Rıdvan Akin, Vedat Köseoğlu, İlhan Tezcan. (2007) Development of in situ melanoma after allogeneic bone marrow transplantation in Griscelli syndrome type II. Pediatric Transplantation 11:7, 792-795
CrossRef97
Manish J. Gandhi, D. Michael Strong. (2007) Donor derived malignancy following transplantation: a review. Cell and Tissue Banking 8:4, 267-286
CrossRef98
Maha Al-Mohaya, Nathaniel Treister, Ons Al-Khadra, Leslie Lehmann, Bonnie Padwa, Sook-Bin Woo. (2007) Calcineurin inhibitor-associated oral inflammatory polyps after transplantation. Journal of Oral Pathology & Medicine 36:9, 570-574
CrossRef99
Thomas Lowe, Smita Bhatia, George Somlo. (2007) Second Malignancies after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 13:10, 1121-1134
CrossRef100
Marguerite T. Parisi, David Mankoff. (2007) Differentiated Pediatric Thyroid Cancer: Correlates With Adult Disease, Controversies in Treatment. Seminars in Nuclear Medicine 37:5, 340-356
CrossRef101
Jennifer R. Brown, Yang Feng, John G. Gribben, Donna Neuberg, David C. Fisher, Peter Mauch, Lee M. Nadler, Arnold S. Freedman. (2007) Long-Term Survival after Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission. Biology of Blood and Marrow Transplantation 13:9, 1057-1065
CrossRef102
R. A. Nash, P. A. McSweeney, L. J. Crofford, M. Abidi, C.-S. Chen, J. D. Godwin, T. A. Gooley, L. Holmberg, G. Henstorf, C. F. LeMaistre, M. D. Mayes, K. T. McDonagh, B. McLaughlin, J. A. Molitor, J. L. Nelson, H. Shulman, R. Storb, F. Viganego, M. H. Wener, J. R. Seibold, K. M. Sullivan, D. E. Furst. (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110:4, 1388-1396
CrossRef103
C Ferry, G Gemayel, V Rocha, M Labopin, H Esperou, M Robin, R P de Latour, P Ribaud, A Devergie, T Leblanc, E Gluckman, A Baruchel, G Socié. (2007) Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplantation 40:3, 219-224
CrossRef104
Christopher R. Cogle, Neil D. Theise, DongTao Fu, Deniz Ucar, Sean Lee, Steven M. Guthrie, Jean Lonergan, Witold Rybka, Diane S. Krause, Edward W. Scott. (2007) Bone Marrow Contributes to Epithelial Cancers in Mice and Humans as Developmental Mimicry. Stem Cells 25:8, 1881-1887
CrossRef105
Hillard M. Lazarus, Patrick J. Stiff, Jeanette Carreras, Brent R. Logan, Luke Akard, Brian J. Bolwell, Richard W. Childs, Robert Peter Gale, John P. Klein, Michael C. Lill, Waleska S. Pérez, Edward A. Stadtmauer, J. Douglas Rizzo. (2007) Utility of Single versus Tandem Autotransplants for Advanced Testes/Germ Cell Cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Biology of Blood and Marrow Transplantation 13:7, 778-789
CrossRef106
Andrei Barasch, John M. Coke. (2007) Cancer therapeutics: an update on its effects on oral health. Periodontology 2000 44:1, 44-54
CrossRef107
Johan Aschan. (2007) Risk assessment in haematopoietic stem cell transplantation: Conditioning. Best Practice & Research Clinical Haematology 20:2, 295-310
CrossRef108
Sakurako Izaki, Hiroaki Goto, Kumiko Okuda, Motoi Matsuda, Yuka Watanabe, Kenichirou Fujioka, Noriyuki Hanzawa, Hiroko Sumita, Hiroyuki Takahashi, Shoko Goto, Sumio Kai, Haruyuki Sekiguchi, Tetsunori Funabiki, Hideki Sasaki, Koichiro Ikuta, Shumpei Yokota. (2007) Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. International Journal of Hematology 86:3, 253-260
CrossRef109
F. Heinzelmann, C. Faul, C. Belka. (2007) Ganzkörperbestrahlung. Der Onkologe 13:5, 397-408
CrossRef110
E P Cohen, W R Drobyski, J E Moulder. (2007) Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation 39:9, 571-572
CrossRef111
Libuse Tauchmanov??, Carmine Selleri, Gennaro De Rosa, Annalidia Sammartino, Costantino Di Carlo, Tittania Musella, Carmen Martorelli, Gaetano Lombardi, Bruno Rotoli, Carmine Nappi, Annamaria Colao. (2007) Estrogen-progestin therapy in women after stem cell transplant. Menopause 14:2, 320-330
CrossRef112
Mareio A. Fonseca, Carol Anne Murdoch-Kinch. (2007) Severe gingival recession and early loss of teeth in a child with chronic graft versus host disease: a case report. Special Care in Dentistry 27:2, 59-63
CrossRef113
Jiro Inagaki, Yoshihisa Nagatoshi, Yoshifumi Kawano, Yusuke Saito, Daijiro Takahashi, Jun Nagayama, Yuichi Shinkoda, Hideki Hirata, Jun Okamura. (2007) Bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin. Pediatric Transplantation 11:2, 180-186
CrossRef114
Herman Suit, Saveli Goldberg, Andrzej Niemierko, Marek Ancukiewicz, Eric Hall, Michael Goitein, Winifred Wong, Harald Paganetti. (2007) Secondary Carcinogenesis in Patients Treated with Radiation: A Review of Data on Radiation-Induced Cancers in Human, Non-human Primate, Canine and Rodent Subjects. Radiation Research 167:1, 12-42
CrossRef115
Genevieve Gallagher, Donna L. Forrest. (2007) Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 109:1, 84-92
CrossRef116
Jonathan Tward, Martha Glenn, Michael Pulsipher, Phillip Barnette, David Gaffney. (2007) Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 48:8, 1482-1495
CrossRef117
Tai Ju Hwang. (2007) Hematopoietic stem cell transplantation : overview for general pediatrician. Korean Journal of Pediatrics 50:7, 613
CrossRef118
Won Bae Kim, Tae Yong Kim, Hyuk Sang Kwon, Won-Jin Moon, Jae Bok Lee, Young Sik Choi, Seok Ki Kim, Sun Wook Kim, Ki-wook Chung, Jung Hwan Baek, Byung Il Kim, Do Joon Park, Dong Gyu Na, Jun Ho Choe, Jae Hoon Chung, Hye Seung Jung, Jeong Han Kim, Kee Hyun Nam, Hang-Seok Chang, Woong Youn Chung, Soon Won Hong, Suck Joon Hong, Jeong Hyun Lee, Ka Hee Yi, Young Suk Jo, Ho-Cheol Kang, Minho Shong, Jin Woo Park, Jong Ho Yoon, Seong Joon Kang, Kwang Woo Lee. (2007) Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. Journal of Korean Endocrine Society 22:3, 157
CrossRef119
Navin Wadehra, Sherif Farag, Brian Bolwell, Patrick Elder, Sam Penza, Matt Kalaycio, Belinda Avalos, Brad Pohlman, Guido Marcucci, Ronald Sobecks, Thomas Lin, Steven Andrèsen, Edward Copelan. (2006) Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 12:12, 1343-1349
CrossRef120
Y. Arai, H. Arai, A. Aoyagi, T. Yamagata, K. Mitani, K. Kubota, H. Kawamata, Y. Imai. (2006) A Solid Tumor of Donor Cell-Origin After Allogeneic Peripheral Blood Stem Cell Transplantation. American Journal of Transplantation 6:12, 3042-3043
CrossRef121
Ramya Ramanujachar, Sue Richards, Ian Hann, David Webb. (2006) Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocols. Pediatric Blood & Cancer 47:6, 748-756
CrossRef122
K.J. Piccinelli, M. Taj, H. H. Lucraft, R. Skinner. (2006) Secondary parotid mucoepidermoid carcinoma after TBI and chemotherapy in childhood AML. Pediatric Blood & Cancer 47:3, 345-346
CrossRef123
D. Bresters, A. B. Versluys. (2006) Late effecten na beenmergtransplantatie. Bijblijven 22:8, 321-327
CrossRef124
Yasutoshi Takeuchi, Kojiro Onizawa, Toshinori Wakatsuki, Kenji Yamagata, Yuichi Hasegawa, Hiroshi Yoshida. (2006) Tongue cancer after bone marrow transplantation. Oral Oncology Extra 42:6, 251-254
CrossRef125
P. W. Finch, J. S. Rubin. (2006) Keratinocyte Growth Factor Expression and Activity in Cancer: Implications for Use in Patients With Solid Tumors. JNCI Journal of the National Cancer Institute 98:12, 812-824
CrossRef126
Brian L. Pipes, Tom Tsang, Shu-Xin Peng, Roger Fiederlein, Michael Graham, David T. Harris. (2006) Telomere length changes after umbilical cord blood transplant. Transfusion 46:6, 1038-1043
CrossRef127
M Cavalier, J A Shmalo, M Yu, S D Billings, R Abonour, R P Nelson. (2006) Skin cancer after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplantation 37:12, 1103-1108
CrossRef128
Seval Yilmaz, Erhan Yilmaz. (2006) Effects of melatonin and Vitamin E on oxidative–antioxidative status in rats exposed to irradiation. Toxicology 222:1-2, 1-7
CrossRef129
Copelan, Edward A., . (2006) Hematopoietic Stem-Cell Transplantation. New England Journal of Medicine 354:17, 1813-1826
Full Text130
Hillard M. Lazarus, Waleska S. Perez, John P. Klein, Craig Kollman, B. Bate-Boyle, Christopher N. Bredeson, Robert Peter Gale, Robert B. Geller, Armand Keating, Mark R. Litzow, David I. Marks, Carole B. Miller, J. Douglas Rizzo, Thomas R. Spitzer, Daniel J. Weisdorf, Mei-Jie Zhang, Mary M. Horowitz. (2006) Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. British Journal of Haematology 132:6, 755-769
CrossRef131
F. Bonnet, P. Morlat. (2006) Cancers et infection par le VIH : quelles associations ?. La Revue de Médecine Interne 27:3, 227-235
CrossRef132
David S. Cooper, Gerard M. Doherty, Bryan R. Haugen, Richard T. Kloos, Stephanie L. Lee, Susan J. Mandel, Ernest L. Mazzaferri, Bryan McIver, Steven I. Sherman, R. Michael Tuttle. (2006) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce. Thyroid 16:2, 109-142
CrossRef133
David S. Cooper, Gerard M. Doherty, Bryan R. Haugen, Richard T. Kloos, Stephanie L. Lee, Susan J. Mandel, Ernest L. Mazzaferri, Bryan McIver, Steven I. Sherman, R. Michael Tuttle. (2006) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 0:0, 060118075408001
CrossRef134
Yohann Loriot, Driss Chaoui, Thierry Dorval, Anne Vincent-Salomon, Livia Lumbroso-Le Rouic, Rémi Dendale, Laurence Desjardins, Christine Levy, Didier Decaudin. (2006) Association between lymphoma and melanoma: report of a single-center series of eight patients and a review of the literature. Leukemia & Lymphoma 47:6, 1023-1028
CrossRef135
Adam Tonakie, Barry L. Shulkin, James C. Sisson, Gregory A. Yanik, Raymond J. Hutchinson. (2006) Radiation-Induced Osteosarcoma and Papillary Carcinoma of the Thyroid. Clinical Nuclear Medicine 31:1, 5-8
CrossRef136
Mitchell E. Horwitz, Keith M. Sullivan. (2006) Chronic graft-versus-host disease. Blood Reviews 20:1, 15-27
CrossRef137
Julio Delgado, Nichola Cooper, Kirsty Thomson, Rafael Duarte, Michael Jarmulowicz, Anna Cassoni, Panagiotis Kottaridis, Karl Peggs, Stephen Mackinnon. (2006) The Importance of Age, Fludarabine, and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 12:1, 75-83
CrossRef138
Wing–Yan Au, Annie Pang, Eunice C. Chan, Kent–Man Chu, Tony W.H. Shek, Yok–Lam Kwong. (2005) Epstein–Barr Virus–Related Gastric Adenocarcinoma: An Early Secondary Cancer Post Hemopoietic Stem Cell Transplantation. Gastroenterology 129:6, 2058-2063
CrossRef139
J.-C. Fricain, V. Sibaud, H. Hafian, C. Deminière, A. Taiëb, J.-M. Boiron. (2005) Les manifestations buccales de la réaction du greffon contre l’hôte. Annales de Dermatologie et de Vénéréologie 132:12, 1017-1025
CrossRef140
Federica Demarosi, Giovanni Lodi, Antonio Carrassi, Davide Soligo, Andrea Sardella. (2005) Oral malignancies following HSCT: Graft versus host disease and other risk factors. Oral Oncology 41:9, 865-877
CrossRef141
Dipak Ghelani, Rima Saliba, Marcos de Lima. (2005) Secondary malignancies after hematopoietic stem cell transplantation. Critical Reviews in Oncology/Hematology 56:1, 115-126
CrossRef142
M Robin, P Guardiola, A Devergie, M Yeshurun, S Shapiro, H Esperou, P Ribaud, V Rocha, E Gluckman, G Socié. (2005) A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 19:9, 1613-1620
CrossRef143
Paul Martin, Debra Friedman. (2005) How can hematopoietic cell transplant centers and referring physicians help each other during long-term follow-up?. Hematology 10:4, 250-254
CrossRef144
Nathaniel S. Treister, Sook-Bin Woo, Eileen W. O’Holleran, Leslie E. Lehmann, Susan K. Parsons, Eva C. Guinan. (2005) Oral Chronic Graft-versus-Host Disease in Pediatric Patients after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 11:9, 721-731
CrossRef145
J. Zanis-Neto, M. E. D. Flowers, C. R. Medeiros, M. A. Bitencourt, C. M. Bonfim, D. C. Setubal, V. Funke, J. Sanders, H. J. Deeg, H. P. Kiem, P. Martin, W. Leisenring, R. Storb, R. Pasquini. (2005) Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia. British Journal of Haematology 130:1, 99-106
CrossRef146
K Shimada, T Yokozawa, Y Atsuta, A Kohno, F Maruyama, K Yano, H Taji, K Kitaori, S Goto, H Iida, Y Morishima, Y Kodera, T Naoe, Y Morishita. (2005) Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplantation 36:2, 115-121
CrossRef147
Erich Vargas-Díez, Amaro García-Díez, Alicia Marín, Jesus Fernández-Herrera. (2005) Life-threatening graft-vs-host disease. Clinics in Dermatology 23:3, 285-300
CrossRef148
Fermin M. Sanchez-Guijo, Luis-Ignacio Sanchez-Abarca, Clara Bueno, Eva Villaron, Natalia Lopez-Holgado, Lourdes Vazquez, Jesus Lopez-Fidalgo, Jose A. Perez-Simon, Maria-Dolores Caballero, Maria-Consuelo del Cañizo, Alberto Orfao, Jesus F. San Miguel. (2005) Long-term Immune Recovery of Patients Undergoing Allogeneic Stem Cell Transplantation: A Comparison with Their Respective Sibling Donors. Biology of Blood and Marrow Transplantation 11:5, 354-361
CrossRef149
J-H Lee, S-J Choi, J-H Lee, Y-S Lee, M Seol, S-G Ryu, J-S Lee, W-K Kim, K-H Lee. (2005) Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplantation 35:8, 755-761
CrossRef150
J J Ortega, T Olivé, C D de Heredia, A Llort. (2005) Secondary malignancies and quality of life after stem cell transplantation. Bone Marrow Transplantation 35, S83-S87
CrossRef151
Yolanda Blanco, Albert Saiz, Enric Carreras, Francesc Graus. (2005) Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. The Lancet Neurology 4:1, 54-63
CrossRef152
Ron Ram, Orit Uziel, Meir Lahav. (2005) The importance of the telomere and telomerase system in hematological malignancies. Leukemia & Lymphoma 46:8, 1121-1135
CrossRef153
John S. Thompson, Claire Pomeroy, Richard J. Kryscio, Stephen A. Brown, Donna Reece, Rita Kramer, Dianna S. Howard, Gary vanZant, Suzanne Humphries, Gordon Phillips. (2004) Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients. Biology of Blood and Marrow Transplantation 10:12, 858-866
CrossRef154
Marcel R. M. van den Brink, Önder Alpdogan, Richard L. Boyd. (2004) Strategies to enhance T-cell reconstitution in immunocompromised patients. Nature Reviews Immunology 4:11, 856-867
CrossRef155
Susan E. Thomas, Raymond J. Hutchinson, Meelie DebRoy, John C. Magee. (2004) Successful renal transplantation following prior bone marrow transplantation in pediatric patients. Pediatric Transplantation 8:5, 507-512
CrossRef156
D. Wolff, V. Anders, R. Corio, T. Horn, W.L. Morison, E. Farmer, G.B. Vogelsang. (2004) Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatology, Photoimmunology and Photomedicine 20:4, 184-190
CrossRef157
RS Gomez, FJGS Pimenta, ALS Guimaraes, LN Souza, UE Salomao, HC de Almeida, RR Vaz. (2004) Effect of bone marrow transplantation on the immunolocalization of p53, hMSH2, and hMLH1 proteins on oral mucosa. Oral Diseases 10:4, 207-211
CrossRef158
Simon F Lacey, Don J Diamond, John A Zaia. (2004) Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biology of Blood and Marrow Transplantation 10:7, 433-447
CrossRef159
V. Bertolle, P. Martin, N. Bleyzac, G. Aulagner. (2004) Intérêt clinique de l’adaptation des posologies du busulfan et de la ciclosporine chez des enfants greffés de moelle osseuse. Annales Pharmaceutiques Françaises 62:3, 165-176
CrossRef160
Maher K. Gandhi, Judy T. Tellam, Rajiv Khanna. (2004) Epstein-Barr virus-associated Hodgkin's lymphoma. British Journal of Haematology 125:3, 267-281
CrossRef161
Michelle M Bishop, John R Wingard. (2004) Thriving after hematopoietic stem cell transplant: a focus on positive changes in quality of life. Expert Review of Pharmacoeconomics & Outcomes Research 4:1, 111-123
CrossRef162
El Ch
rif Ibrahim, S
CrossRef163
JENNIFER R BROWN, GUYLAINE GAUDET, JONATHAN W FRIEDBERG, DONNA NEUBERG, PETER MAUCH, JEFFREY L KUTOK, TAK TAKVORIAN, DAVID C FISHER, JOHN G GRIBBEN, HELEN KIM, LEE M NADLER, ARNOLD S FREEDMAN. (2004) Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 45:2, 315-320
CrossRef164
Carole Rubino, Elisabeth Adjadj, Sylvie Gu
CrossRef165
Christèle Ferry, Gérard Socié. (2003) Busulfan-cyclophosphamide versus total body irradiation–cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned?. Experimental Hematology 31:12, 1182-1186
CrossRef166
Teri Vega-Stromberg. (2003) Chemotherapy-induced Secondary Malignancies. Journal of Infusion Nursing 26:6, 353-361
CrossRef167
Huib M Vriesendorp. (2003) Aims of conditioning. Experimental Hematology 31:10, 844-854
CrossRef168
Baron, Frederic, Dresse, Marie-Françoise, Beguin, Yves, . (2003) Transmission of Chronic Myeloid Leukemia through Peripheral-Blood Stem-Cell Transplantation. New England Journal of Medicine 349:9, 913-914
Full Text169
Leslie L. Robison, Smita Bhatia. (2003) Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. British Journal of Haematology 122:3, 345-359
CrossRef170
Smita Bhatia. (2003) Late effects among survivors of leukemia during childhood and adolescence. Blood Cells, Molecules, and Diseases 31:1, 84-92
CrossRef171
N. S. Shilnikova, D. L. Preston, E. Ron, E. S. Gilbert, E. K. Vassilenko, S. A. Romanov, I. S. Kuznetsova, M. E. Sokolnikov, P. V. Okatenko, V. V. Kreslov, N. A. Koshurnikova. (2003) Cancer Mortality Risk among Workers at the Mayak Nuclear Complex. Radiation Research 159:6, 787-798
CrossRef172
Victor M. Aquino, Gail Tomlinson, Arthur G. Weinberg, Debra A. Eshelman. (2003) Extraskeletal myxoid chondrosarcoma as a second malignancy after bone marrow transplantation. Medical and Pediatric Oncology 40:5, 336-337
CrossRef173
Shelby Langer, Janet Abrams, Karen Syrjala. (2003) Caregiver and patient marital satisfaction and affect following hematopoietic stem cell transplantation: a prospective, longitudinal investigation. Psycho-Oncology 12:3, 239-253
CrossRef174
Andy CY Li, Saman Warnakulasuriya, Richard PH Thompson. (2003) Neoplasia of the tongue in a patient with Crohn's disease treated with azathioprine. European Journal of Gastroenterology & Hepatology 15:2, 185-187
CrossRef175
Lillian Sung, Rena Buckstein, John J. Doyle, Michael Crump, Allan S. Detsky. (2003) Treatment options for patients with acute myeloid leukemia with a matched sibling donor. Cancer 97:3, 592-600
CrossRef176
Hendrikus G.J Krouwer, Eelco F.M Wijdicks. (2003) Neurologic complications of bone marrow transplantation. Neurologic Clinics 21:1, 319-352
CrossRef177
Martine Szyper-Kravitz, Orit Uziel, Hava Shapiro, Judith Radnay, Tami Katz, Jacob M. Rowe, Michael Lishner, Meir Lahav. (2003) Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34+ haematopoietic cells and may prevent telomere attrition after chemotherapy. British Journal of Haematology 120:2, 329-336
CrossRef178
V. Andreani, M.A. Richard, D. Blaise, J. Gouvernet, J.J. Grob. (2002) Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi. British Journal of Dermatology 147:3, 433-441
CrossRef179
Libuse Tauchmanov
CrossRef180
Antin, Joseph H., . (2002) Long-Term Care after Hematopoietic-Cell Transplantation in Adults. New England Journal of Medicine 347:1, 36-42
Full Text181
Alison D. Leiper. (2002) Non-endocrine late complications of bone marrow transplantation in childhood: part II. British Journal of Haematology 118:1, 23-43
CrossRef182
Catharina Wesseling, Eero Pukkala, Kaisa Neuvonen, Timo Kauppinen, Paolo Boffetta, Timo Partanen. (2002) Cancer of the Brain and Nervous System and Occupational Exposures in Finnish Women. Journal of Occupational and Environmental Medicine 44:7, 663-668
CrossRef183
Alison D. Leiper. (2002) Non-endocrine late complications of bone marrow transplantation in childhood: part I. British Journal of Haematology 118:1, 3-22
CrossRef184
Keigo Hamahata, Masaru Kubota, Ikuya Usami, Ying-Wei Lin, Ken Shimizu, Akira Morimoto, Tatsutoshi Nakahata. (2002) Somatic cell mutation in pediatric patients undergoing allogeneic bone marrow transplantation. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 517:1-2, 21-28
CrossRef185
Jean E. Sanders. (2002) Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation. International Journal of Hematology 76:S2, 15-28
CrossRef186
Richard K. Burt, Shimon Slavin, William H. Burns, Alberto M. Marmont. (2002) Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure?. International Journal of Hematology 76:S1, 226-247
CrossRef187
John M. Goldman, Mary M. Horowitz. (2002) The International Bone Marrow Transplant Registry. International Journal of Hematology 76:S1, 393-397
CrossRef188
Sebastien Maury, Jean-Yves Mary, Claire Rabian, Michael Schwarzinger, Antoine Toubert, Catherine Scieux, Maryvonnick Carmagnat, Helene Esperou, Patricia Ribaud, Agnes Devergie, Philippe Guardiola, Patrick Vexiau, Dominique Charron, Eliane Gluckman, Gerard Socie. (2001) Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. British Journal of Haematology 115:3, 630-641
CrossRef189
Berg, Karin D., Brinster, Nooshin K., Huhn, Karen M., Goggins, Michael G., Jones, Richard J., Makary, Adel, Murphy, Kathleen M., Griffin, Constance A., Rosenblum-Vos, Lynne S., Borowitz, Michael J., Nousari, Hossein C., Eshleman, James R., . (2001) Transmission of a T-Cell Lymphoma by Allogeneic Bone Marrow Transplantation. New England Journal of Medicine 345:20, 1458-1463
Full Text190
P. Mollee, N. Woodward, S. Durrant, L. Lockwood, E. A. Gillett, J. Morton, J. Rowell. (2001) Single institution outcomes of treatment of severe aplastic anaemia. Internal Medicine Journal 31:6, 337-342
CrossRef191
Kim Margolin, Tim Synold, Jeff Longmate, James H. Doroshow. (2001) Methodologic guidelines for the design of high-dose chemotherapy regimens. Biology of Blood and Marrow Transplantation 7:8, 414-432
CrossRef192
Mwanda W. Otieno, Scot C. Remick, Christopher Whalen. (2001) Adult Burkitt's lymphoma in patients with and without human immunodeficiency virus infection in Kenya. International Journal of Cancer 92:5, 687-691
CrossRef193
John Moppett, Anthony Oakhill, Andrew W. Duncan. (2001) Second malignancies in children: the usual suspects?. European Journal of Radiology 38:3, 235-248
CrossRef194
Roy E. Shore. (2001) Radiation-induced skin cancer in humans. Medical and Pediatric Oncology 36:5, 549-554
CrossRef195
Gerard Socie, Jean-Yves Mary, Helene Esperou, Dominique Vexiau Robert, Selim Aractingi, Patricia Ribaud, Agnes Devergie, , Patrice Boudou, Beryl Cathelinau, Eliane Gluckman, Patrick Vexiau. (2001) Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology 113:1, 194-201
CrossRef196
Je-Jung Lee, Hoon Kook, Ik-Joo Chung, Jeung-A Na, Moo-Rim Park, Tai-Ju Hwang, Jae-Yong Kwak, Sang-Kyun Sohn, Hyeoung-Joon Kim. (2001) Telomere length changes in patients with aplastic anaemia. British Journal of Haematology 112:4, 1025-1030
CrossRef197
William B. Goggins, Dianne M. Finkelstein, Hensin Tsao. (2001) Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer 91:4, 874-880
CrossRef198
John Moppett, Anthony Oakhill, Andrew W. Duncan. (2001) Second malignancies in children: the usual suspects?. European Journal of Radiology 37:2, 95-108
CrossRef199
H. C. Kluin-Nelemans, V. Zagonel, A. Anastasopoulou, D. Bron, K. J. Roozendaal, E. M. Noordijk, H. Musson, I. Teodorovic, B. Maes, A. Carbone, P. Carde, J. Thomas. (2001) Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study. JNCI Journal of the National Cancer Institute 93:1, 22-30
CrossRef200
Charles M. Rudin, Craig B. Thompson. (2001) Transcriptional activation of short interspersed elements by DNA-damaging agents. Genes, Chromosomes and Cancer 30:1, 64-71
CrossRef201
Catherine Wheeler, Anwar Khurshid, Joseph Ibrahim, Anthony Elias, Peter Mauch, Kenneth Ault, Joseph Antin. (2001) Incidence of Post Transplant Myelodysplasia/Acute Leukemia in Non-Hodgkin's Lymphoma Patients Compared with Hodgkin's Disease Patients Undergoing Autologous Transplantation Following Cyclophosphamide, Carmustine, and Etoposide (CBV). Leukemia & Lymphoma 40:5-6, 499-509
CrossRef202
G.A. Hale, G.L. Phillips. (2000) Allogeneic stem cell transplantation for the non-Hodgkin’s lymphomas and Hodgkin’s disease. Cancer Treatment Reviews 26:6, 411-427
CrossRef203
(2000) Is it time to reduce toxicity by�non-myeloablative conditioning for allogeneic stem cell transplantation in children?. Pediatric Transplantation 4:4, 247-251
CrossRef204
John Barrett, Richard Childs. (2000) Non-myeloablative stem cell transplants. Annotation. British Journal of Haematology 111:1, 6-17
CrossRef205
John Barrett, Richard Childs. (2000) Non-myeloablative stem cell transplants. British Journal of Haematology 111:1, 6-17
CrossRef206
I. Levav, R. Kohn, J. Iscovich, J. H. Abramson, W. Y. Tsai, D. Vigdorovich. (2000) Cancer incidence and survival following bereavement. American Journal of Public Health 90:10, 1601-1607
CrossRef207
Arnon Nagler, Reuven Or, Elizabeth Naparstek, Gabor Varadi, Shimon Slavin. (2000) Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Experimental Hematology 28:9, 1096-1104
CrossRef208
Amanda L. Kim, Conrad V. Fernandez, Wenda L. Greer, David Hogg, Norman J. Lassam, Lothar Resch. (2000) Concurrent Acute Lymphoblastic Leukemia and Juvenile Pilocytic Astrocytoma in a Pediatric Patient. Journal of Pediatric Hematology/Oncology 22:5, 451-453
CrossRef209
Alberto M. Marmont. (2000) New Horizons in the Treatment of Autoimmune Diseases: Immunoablation and Stem Cell Transplantation. Annual Review of Medicine 51:1, 115-134
CrossRef210
Linda D. Cooley, David A. Sears, Mark M. Udden, Wilbur R. Harrison, Kelty R. Baker. (2000) Donor cell leukemia: Report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. American Journal of Hematology 63:1, 46-53
CrossRef211
Mary M Horowitz. (2000) Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Seminars in Hematology 37:1, 30-42
CrossRef212
Alison D Lejper. (1999) Stem-cell transplantation. The Lancet 354:9190, 1644-1645
CrossRef213
Shaun McCann, Jane Apperley, Amnon Cohen, Hans-Joachim Kolb, Gerard Socie. (1999) Late effects of transplantation. The Lancet 354:9180, 778
CrossRef214
Julie A Butcher, Sundaram Hariharan, Mark B Adams, Christopher P Johnson, Allan M Roza, Eric P Cohen. (1999) Renal transplantation for end-stage renal disease following bone marrow transplantation: A report of six cases, with and without immunosuppression. Clinical Transplantation 13:4, 330-335
CrossRef215
Thomas, E. Donnall, . (1999) Does Bone Marrow Transplantation Confer a Normal Life Span?. New England Journal of Medicine 341:1, 50-51
Full Text216
Socié, Gérard, Stone, Judith Veum, Wingard, John R., Weisdorf, Daniel, Henslee-Downey, P. Jean, Bredeson, Christopher, Cahn, Jean-Yves, Passweg, Jakob R., Rowlings, Philip A., Schouten, Harry C., Kolb, Hans-Jochem, Bender-Götze, Christine, Camitta, Bruce M., Godder, Kamar, Horowitz, Mary M., Wayne, Alan S., Klein, John P., . (1999) Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine 341:1, 14-21
Full Text217
Mark R. Somerfield, Michael E. Stefanek, Thomas J. Smith, Jennifer J. Padberg. (1999) A systems model for adaptation to somatic distress among cancer survivors. Psycho-Oncology 8:4, 334-343
CrossRef218
Shawn E. Holt, Jerry W. Shay. (1999) Role of telomerase in cellular proliferation and cancer. Journal of Cellular Physiology 180:1, 10-18
CrossRef219
Alison D Leiper. (1999) What is in store after stem-cell transplantation?. The Lancet 353:9164, 1544-1545
CrossRef220
A Gratwohl. (1999) From autoimmunity to stem cell transplantation. Critical Reviews in Oncology/Hematology 30:2, 159-172
CrossRef221
Jens J. Froelich, Folker R. G. Schneller, Rudolf K. Zahn. (1999) The Influence of Radiation and Chemotherapy-Related DNA Strand Breaks on Carcinogenesis: An Evaluation. Clinical Chemistry and Laboratory Medicine 37:4, 403-408
CrossRef222
Julianne Byrne. (1999) Long-term genetic and reproductive effects of ionizing radiation and chemotherapeutic agents on cancer patients and their offspring. Teratology 59:4, 210-215
CrossRef223
B DUBRAY, P GIRAUD, S HELFRE, R DENDALE, J COSSET. (1999) Bases biologiques de l'irradiation corporelle totale. Cancer/Radiothérapie 3:2, 154-161
CrossRef224
(1999) Is endocrinological assessment and follow-up of children after bone marrow transplantation necessary? How, and for how long?. Pediatric Transplantation 3:1, 1-4
CrossRef225
Steven L. Craig, Alvan R. Feinstein. (1999) Antecedent Therapy Versus Detection Bias as Causes of Neoplastic Multimorbidity. American Journal of Clinical Oncology 22:1, 51-56
CrossRef226
Nico Wulffraat, Annet van Royen, Marc Bierings, Jaak Vossen, Wietse Kuis. (1999) Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. The Lancet 353:9152, 550-553
CrossRef227
Helma Motherby, Bernd Roß, Mary Kube, Ulrich Germing, Axel Heyll, Carlo Aul, Stefan Braunstein, Helmut Erich Gabbert, Alfred Böcking. (1998) Pleural carcinosis confirmed by adjuvant cytological methods: A case report. Diagnostic Cytopathology 19:5, 370-374
CrossRef228
Mark P. Little, Florent de Vathaire, Akthar Shamsaldin, Odile Oberlin, Sarah Campbell, Emmanuel Grimaud, Jean Chavaudra, Richard G. E. Haylock, Colin R. Muirhead. (1998) Risks of brain tumour following treatment for cancer in childhood: Modification by genetic factors, radiotherapy and chemotherapy. International Journal of Cancer 78:3, 269-275
CrossRef229
James J Goedert, Timothy R Coté, Phillip Virgo, Steven M Scoppa, Douglas W Kingma, Mitchell H Gail, Elaine S Jaffe, Robert J Biggar. (1998) Spectrum of AIDS-associated malignant disorders. The Lancet 351:9119, 1833-1839
CrossRef230
Robert F Wynn, Michael A Cross, Claire Hatton, Andrew M Will, Linda S Lashford, T Michael Dexter, Nydia G Testa. (1998) Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. The Lancet 351:9097, 178-181
CrossRef231
Jerry W Shay. (1998) Accelerated telomere shortening in bonemarrow recipients. The Lancet 351:9097, 153-154
CrossRef232
T GIRINSKY, J COSSET. (1997) Les effets tardifs pulmonaires et cardiaques induits par les radiations ionisantes seules ou associ
CrossRef233
Detlev Latz, Michael F. Wannenmacher. (1997) Solide Malignome nach Knochenmarktransplantation. Strahlentherapie und Onkologie 173:10, 530-531
CrossRef234
(1997) Solid Cancers after Bone Marrow Transplantation. New England Journal of Medicine 337:5, 345-346
Full Text235
Schenkein, David P., , Schwartz, Robert S., . (1997) Neoplasms and Transplantation — Trading Swords for Plowshares. New England Journal of Medicine 336:13, 949-950
Full Text
- Letters
